A new blueprint for biomanufacturing: How modular process intensification will define the next decade

Jan Schäfer and Dr. Geert Lissens, Sartorius Stedim Biotech explain how modular process intensification will define the next decade. 

The biopharmaceutical manufacturing industry is under increasing pressure as drug development costs rise and profit margins shrink, driving a shift away from conventional batch-based production toward intensified approaches. Over recent decades, single-use technologies have become widely adopted, delivering flexibility, lower capital investment, and reduced contamination risks. Today, process intensification, built on automation, integration, and…